J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025 following positive data from the SunRISe-1 trial.

The US FDA has cleared BlackfinBio's application for a Phase I/II trial of BFB-101, an AAV gene therapy designed to treat ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...

Renibus has completed subject enrolment for the Phase III PROTECT trial of RBT-1 in minimising post-operative risk in cardiac ...

Clinical ink has launched the AI-powered, fully integrated analytics dashboard, TrialLens, which is designed to interpret eCOA data.

The trial is structured to assess the preliminary efficacy and safety of the therapy in individuals with AML. Credit: Papa Annur/Shutterstock. CERo Therapeutics has announced that Colorado Blood ...

Caribou is reducing its workforce by approximately 32%. Credit: tadamichi via Getty Images. Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued ...

At ESCMID 2025, early data suggest that Assembly Biosciences’ ABI-5366 could redefine the treatment landscape for recurrent genital herpes (RGH).

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...